DOI: https://doi.org/10.22141/2224-0713.8.110.2019.187891

Pain and depression: new possibilities of pharmacotherapy of chronic psychogenic pain syndromes

S.G. Burchinsky

Abstract


Тhe present paper considers modern views on the problem of chronic psychogenic pain and its association with depressive disorders. From this point of view, the requirements to the choice of optimal pharmacological tool within comprehensive therapy of psychogenic pain and depression have been analyzed. A main attention is paid to the mechanisms of action and peculiarities of the clinical use of duloxetine (Dyulok) — antidepressant with unique mechanism of action and clinico-pharmacological properties that make possible to realize the strategy of pathogenetic pharmacotherapy in the treatment of depression and chronic psychogenic pain syndromes. A clinical efficacy of duloxetine (Dyulok), its safety characteristics, and recommendations of practical use have been considered in detail.

Keywords


chronic psychogenic pain syndromes; depression; antidepressants; duloxetine

References


Бурчинский С.Г. Фармакотерапия постинсультной депрессии: проблема и критерии выбора антидепрессанта. НейроNews. 2018. № 6. С. 37-41.

Вертоградова О.П., Моисейчикова О.В. Особенности динамики депрессии при лечении симбалтой. Соц. клин. психиат. 2009. № 4. С. 42-46.

Вознесенская Т.Г. Хроническая боль и депрессия. Журн. неврол. психиат. 2008. Т. 108. № 11. С. 98-101.

Гапонова О.Г. Применение антидепрессантов в терапии абдоминального болевого синдрома. Ліки України. 2012. № 3-4. С. 25-29.

Данилов А.Б., Исагулян Э.Д., Макашова Е.С. Психогенная боль. Журн. неврол. психиат. 2018. т. 118. № 11. С. 103-108.

Дюкова Г.М., Погромов А.П., Леонова М.Л. и др. Эффективность антидепрессанта двойного действия дулоксетина в терапии функциональных расстройств желудочно-кишечного тракта. Мед. совет. 2014. № 3. С. 78-80.

Мамчур В.Й., Хом’як О.В. Депресія та біль: деякі питання коморбідності та лікування. Морфологія. 2011. Т. V. № 3. С. 24-34.

Павленко А.Ю., Хижняк А.А. Болевой синдром: патофизиологические механизмы развития и методы воздействия на этапах оказания медицинской помощи. Медицина неотложн. сост. 2006. № 1. С. 29-39.

Слободин Т.Н. Патогенез и современные подходы к лечению хронической боли. Укр. вісн. психоневрол. 2012. Т. 20. Вип. 4. С. 106-113.

Amone D., Melntosh A.M., Ebmeier K.P. et al. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur. Neuropsychopharmacol. 2012. Vol. 22. P. 116-132.

Ball S.G., Desalah D., Zhang C. et al. Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context. 2013. doi 10.7573/dic.212245.

Begre S., Traber M., Gerber M. et al. Change in pain severity with open label venlafaxine use in patients with a depressive sympto-matology: an observational study in primary care. Eur. Psychiat. 2008. Vol. 23. P. 178-186.

Bushnell M.C., Ceko M., Low L.A. Cognitive and emotio-nal control of pain and its disruption in chronic pain. Nature. 2013. Vol. 14. P. 502-511.

Bymaster F.P., Lee T.C., Khadler M.P. et al. The dual transporter inhibitor duloxetine: a review of its clinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des. 2005. Vol. 11. P. 1475-1493.

Cipriani A., Koesters M., Furukawa T.A. et al. Duloxetine versus other anti-depressive agents for depression Cochrane Database Syst. Rev. 2012. CD006533. doi: 1002/1465.

Delgado P.L. Serotonin noradrenaline reuptake inhibitors: new hope for the treatment of chronic pain. Int. J. Psychiat. Clin. Pract. 2006. Vol. 10. Suppl. 2. P. 16-21.

Dharmshaktu P., Tayal V., Kalra B.S. Efficacy of antidepressants as analgesics: a review. J. Clin. Pharmacol. 2012. Vol. 52. P. 6-17.

Dunner D.L., Goldstein D.J., Mallincroft C. et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety. 2003. Vol. 18. P. 53-61.

Gartlehner G., Thaler K., Hansen R.A. et al. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Drug Saf. 2009. Vol. 32. P. 1159-1173.

Fasick V., Spengler R.N., Samankan S. et al. The hippocampus and TNF: common links between chronic pain and depression. Neurosci. Biobehav. Rev. 2015. Vol. 53. P. 139-159.

Fava M., Mallincroft C.H., Detke M.J. et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiat. 2004. Vol. 65. P. 521-530.

Fishbain D.A., Cole B., Lewis J.E. et al. Does pain interfere with antidepressant depression treatment response and remission in patients with depression and pain? An evidence-based structured review. Pain Med. 2014. Vol. 15. P. 1522-1539.

Frampton J.E., Plosker G.L. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007. Vol. 21. P. 581-609.

Jaracz J., Gattner K., Jaracz K. et al. Unexplained painful physical symptoms in patients with major depressive disorder: prevalence, pathophysiology and management. CNS Drugs. 2016. Vol. 30. doi: 10.1007/s40263-016-0328-5.

Letchard J.P. Psychogenic pain syndromes: new insights of pathophysiology and treatment. Neurobehavioral Medicine: from theory — to practice. N.Y.: Winfrid&Co, 2016. P. 164-183.

Li G., Wang X., Ma D. Vortioxetine versus duloxetine in the treatment of patients with major depressive disorder: a meta-analysis of randomized controlled trials. Clin. Drug Invest. 2016. Vol. 36. P. 509-517.

Li X., Zhu I., Zhou C. et al. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: a meta-analysis. PLoS One. 2018. Vol. 13. doi: 10.1371/journal.pone.0194.

Martinez J.M., Katon W., Greist J.H. et al. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a mode-rate-to-severe depression episode. Int. Clin. Psychopharmacol. 2012. Vol. 27. P. 17-26.

McCrae C.S., O’Shea A.M., Boissoneault J. et al. Fibromyalgia patients have reduced hippocampal volume compared with healthy controls. J. Pain Res. 2015. Vol. 8. P. 47-52.

McIntyre R., Lophaven S., Olsen C. Randomized, double-blind, placebo-controlled study of the efficacy of duloxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). Neuropsychopharmacology. 2013. Vol. 38. P. 380-381.

Norman T.R., Olver J.S. Continuation treatment of major depressive disorder: is there a case for duloxetine? Drug Des. Devel. Ther. 2010. Vol. 18. P. 19-31.

Papakostas G.I., Thase M.E., Fava M. et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiat. 2007. Vol. 62. P. 1217-1227.

Perahia D.G., Pritchett Y.L., Desaiah D. et al. Efficacy of duloxetine in painful symptoms; an analgesic or antidepressive effect? Int. Clin. Psychopharmacol. 2006. Vol. 21. P. 311-317.

Perahia D.G., Quail D., Desaiah D. et al. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J. Psychiat. Res. 2009. Vol. 43. P. 512-518.

Ramsberg J., Asseburg C., Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One. 2012. Vol. 7. CD 42003.

Raskin J., Pritchett Y.L., Wang C. et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005. Vol. 6. P. 346-356.

Rej S., Dew M.A., Karp J.F. Treating concurrent chronic low back pain and depression with low-dose venlafaxine: an initial identification of “easy-to-use” clinical predictors of early response. Pain Med. 2014. Vol 15. P. 1154-1162.

Shelton R.C. Serotonin and norepinephrine reuptake inhibitors. Handb. Exp. Pharmacol. 2019. Vol. 250. P. 145-180.

Walitt B., Urrutia G., Nishishinya M.B. et al. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst. Rev. 2015. 6. CD011735.




Copyright (c) 2020 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта